342 related articles for article (PubMed ID: 19466903)
41. Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches.
Savelieva I; Camm J
Europace; 2008 Jun; 10(6):647-65. PubMed ID: 18515286
[TBL] [Abstract][Full Text] [Related]
42. Mechanisms of atrial fibrillation termination by pure sodium channel blockade in an ionically-realistic mathematical model.
Kneller J; Kalifa J; Zou R; Zaitsev AV; Warren M; Berenfeld O; Vigmond EJ; Leon LJ; Nattel S; Jalife J
Circ Res; 2005 Mar; 96(5):e35-47. PubMed ID: 15731458
[TBL] [Abstract][Full Text] [Related]
43. Current antiarrhythmic drugs: an overview of mechanisms of action and potential clinical utility.
Singh BN
J Cardiovasc Electrophysiol; 1999 Feb; 10(2):283-301. PubMed ID: 10090235
[TBL] [Abstract][Full Text] [Related]
44. Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent.
Fedida D
Expert Opin Investig Drugs; 2007 Apr; 16(4):519-32. PubMed ID: 17371199
[TBL] [Abstract][Full Text] [Related]
45. Mechanisms of atrial fibrillation termination by rapidly unbinding Na+ channel blockers: insights from mathematical models and experimental correlates.
Comtois P; Sakabe M; Vigmond EJ; Munoz M; Texier A; Shiroshita-Takeshita A; Nattel S
Am J Physiol Heart Circ Physiol; 2008 Oct; 295(4):H1489-504. PubMed ID: 18676686
[TBL] [Abstract][Full Text] [Related]
46. Blockers of the Kv1.5 channel for the treatment of atrial arrhythmias.
Brendel J; Peukert S
Curr Med Chem Cardiovasc Hematol Agents; 2003 Oct; 1(3):273-87. PubMed ID: 15326917
[TBL] [Abstract][Full Text] [Related]
47. Atrial-selective K
Ravens U
Can J Physiol Pharmacol; 2017 Nov; 95(11):1313-1318. PubMed ID: 28738160
[TBL] [Abstract][Full Text] [Related]
48. Electrophysiological effects of flecainide and sotalol in the human atrium during persistent atrial fibrillation.
Kirchhof P; Engelen M; Franz MR; Ribbing M; Wasmer K; Breithardt G; Haverkamp W; Eckardt L
Basic Res Cardiol; 2005 Mar; 100(2):112-21. PubMed ID: 15696400
[TBL] [Abstract][Full Text] [Related]
49. [Perspectives and limitations in the treatment of vagus-induced atrial fibrillation. Insights from cellular pharmacology].
Brandts B; Van Bracht M; Dirkmann D; Borchard R; Wickenbrock I; Prull MW; Meine M; Trappe HJ
Med Klin (Munich); 2004 Jul; 99(7):341-6. PubMed ID: 15322712
[TBL] [Abstract][Full Text] [Related]
50. New directions in antiarrhythmic drug therapy for atrial fibrillation.
Heijman J; Voigt N; Dobrev D
Future Cardiol; 2013 Jan; 9(1):71-88. PubMed ID: 23259476
[TBL] [Abstract][Full Text] [Related]
51. Kv1.5 Inhibitors for Treatment of Atrial Fibrillation: A Tradeoff between Selectivity and Non-selectivity.
Guo X; Chen W; Sun H; You Q
Curr Top Med Chem; 2016; 16(16):1843-54. PubMed ID: 26975505
[TBL] [Abstract][Full Text] [Related]
52. Can inhibition of IKur promote atrial fibrillation?
Burashnikov A; Antzelevitch C
Heart Rhythm; 2008 Sep; 5(9):1304-9. PubMed ID: 18774108
[TBL] [Abstract][Full Text] [Related]
53. Antiarrhythmic agents for atrial fibrillation: focus on prolonging atrial repolarization.
Singh BN; Mody FV; Lopez B; Sarma JS
Am J Cardiol; 1999 Nov; 84(9A):161R-173R. PubMed ID: 10568677
[TBL] [Abstract][Full Text] [Related]
54. Atria-selective antiarrhythmic drugs in need of alliance partners.
Peyronnet R; Ravens U
Pharmacol Res; 2019 Jul; 145():104262. PubMed ID: 31059791
[TBL] [Abstract][Full Text] [Related]
55. [Vernakalant--a new drug for pharmacological conversion of atrial fibrillation].
Hinneburg I
Med Monatsschr Pharm; 2011 May; 34(5):154-8. PubMed ID: 21644373
[TBL] [Abstract][Full Text] [Related]
56. Novel pharmacological targets for the rhythm control management of atrial fibrillation.
Burashnikov A; Antzelevitch C
Pharmacol Ther; 2011 Dec; 132(3):300-13. PubMed ID: 21867730
[TBL] [Abstract][Full Text] [Related]
57. Increased atrial effectiveness of flecainide conferred by altered biophysical properties of sodium channels.
O' Brien S; Holmes AP; Johnson DM; Kabir SN; O' Shea C; O' Reilly M; Avezzu A; Reyat JS; Hall AW; Apicella C; Ellinor PT; Niederer S; Tucker NR; Fabritz L; Kirchhof P; Pavlovic D
J Mol Cell Cardiol; 2022 May; 166():23-35. PubMed ID: 35114252
[TBL] [Abstract][Full Text] [Related]
58. Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation.
Burashnikov A; Di Diego JM; Sicouri S; Ferreiro M; Carlsson L; Antzelevitch C
Heart Rhythm; 2008 Dec; 5(12):1735-42. PubMed ID: 19084813
[TBL] [Abstract][Full Text] [Related]
59. Late INa Inhibition as an Antiarrhythmic Strategy.
Burashnikov A
J Cardiovasc Pharmacol; 2017 Sep; 70(3):159-167. PubMed ID: 28654510
[TBL] [Abstract][Full Text] [Related]
60. Pilsicainide for atrial fibrillation.
Kumagai K; Nakashima H; Tojo H; Yasuda T; Noguchi H; Matsumoto N; Ogawa M; Saku K
Drugs; 2006; 66(16):2067-73. PubMed ID: 17112301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
